What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Carcinoma, Internal medicine, Cancer, Oncology and Surgery are his primary areas of study.
Sergio Pecorelli interconnects Gynecology, Corpus Uteri, Cervix and Neoplasm Invasiveness in the investigation of issues within Carcinoma.
His Internal medicine research integrates issues from Placebo and Transdermal.
He has included themes like Stage, Cancer research, Vulvar Diseases and Pathology in his Cancer study.
The concepts of his Oncology study are interwoven with issues in Chemotherapy, Cisplatin, Ovary, Proportional hazards model and Survival analysis.
The Surgery study combines topics in areas such as Optimal Debulking, Clinical trial and Suboptimal Debulking.
His most cited work include:
- Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium (1790 citations)
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer (1401 citations)
- Carcinoma of the ovary. (1028 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Oncology, Ovarian cancer, Cancer and Pathology.
His is involved in several facets of Internal medicine study, as is seen by his studies on Chemotherapy, Carcinoma, Cisplatin and Cervical cancer.
Chemotherapy is a subfield of Surgery that he tackles.
His Carcinoma study typically links adjacent topics like Cervix.
His Oncology study incorporates themes from Paclitaxel, Endometrial cancer, Epithelial ovarian cancer, Stage and Radiation therapy.
His Ovarian cancer research is multidisciplinary, incorporating perspectives in Hazard ratio, Cancer research, Gynecology and Ovary.
He most often published in these fields:
- Internal medicine (36.54%)
- Oncology (28.85%)
- Ovarian cancer (25.32%)
What were the highlights of his more recent work (between 2011-2021)?
- Cancer research (17.63%)
- Internal medicine (36.54%)
- Ovarian cancer (25.32%)
In recent papers he was focusing on the following fields of study:
Sergio Pecorelli spends much of his time researching Cancer research, Internal medicine, Ovarian cancer, Oncology and Pathology.
His research in Cancer research intersects with topics in Ovarian carcinoma, Microarray, Gene expression profiling and Immunotherapy.
Internal medicine connects with themes related to Medical prescription in his study.
His Ovarian cancer study necessitates a more in-depth grasp of Cancer.
His work deals with themes such as Gynecology and Disease, which intersect with Cancer.
His study looks at the relationship between Oncology and topics such as Carcinoma, which overlap with Endometrial cancer.
Between 2011 and 2021, his most popular works were:
- Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. (199 citations)
- Interventional tools to improve medication adherence: review of literature (140 citations)
- Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition (96 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Sergio Pecorelli mostly deals with Cancer research, Uterine serous carcinoma, Internal medicine, Gerontology and Disease.
His Cancer research research is multidisciplinary, incorporating perspectives in Gene expression profiling, Oncogene, Microarray, microRNA and Ovarian cancer.
His research investigates the connection between Ovarian cancer and topics such as Clear cell that intersect with issues in Cancer.
The various areas that Sergio Pecorelli examines in his Uterine serous carcinoma study include Molecular biology, Downregulation and upregulation, Complement system and Immunology.
His Internal medicine research includes themes of Endocrinology and Oncology.
His Carcinoma research is multidisciplinary, relying on both Histone H2A, CHD4, Histone, Gene cluster and PTEN.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
